“Our second quarter of 2025 and recent weeks have been a productive period for PDS Biotech, highlighted by the continued progress in our VERSATILE-003 Phase 3 clinical trial evaluating PDS0101 in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma. Highlights also included the announcement and presentation of data from our VERSATILE-002 trial which we believe demonstrates the potential durable clinical benefit of PDS0101,” said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. “We look forward to publishing the full data set for this trial later this year, as we continue to progress our VERSATILE-003 trial, the only registrational stage trial specifically targeting HPV16-positive HNSCC patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDSB Upcoming Earnings Report: What to Expect?
- Promising Advancements in PDS Biotechnology’s Therapeutic Developments Justify Buy Rating
- PDS Biotechnology Completes Recruitment for Clinical Trial
- PDS Biotech completes patient recruitment in Stage 1 colorectal cancer trial
- Optimistic Buy Rating for PDS Biotechnology Driven by Promising Versamune HPV Data and Unmet Needs in HPV16+ HNSCC